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Oral renin inhibitors
For almost 20 years, the development of oral renin inhibitors 
met huge problems. Th e clinical development of aliskiren 
signifi es a breakthrough. However, the search for agents with 
improved oral bioavailability, specifi city for human renin, and 
effi  cacy continues.
As compared with angiotensin-converting enzyme (ACE) 
inhibitors, renin inhibitors have fewer side eff ects, but as with 
angiotensin-receptor blockers, they might be less powerful 
in reducing blood pressure, because they do not block the 
degradation of bradykinin. Renin inhibitors might be clinically 
indicated in combination therapy with drugs that lead to a 
reactive increase in the plasma renin activity, such as diuretics, 
ACE inhibitors, and angiotensin-receptor blockers. Renin 
inhibitors might be useful in younger and white patients, who 
have a more active renin system than older and non-white 
people. Renin inhibitors might also be useful in patients 
intolerant of ACE inhibitors, for the treatment of disorders in 
which angiotensin II contributes to the pathogenesis, and for 
secondary prevention of cardiovascular diseases. Moreover, 
renin inhibitors off er additional safety for patients with 
cardiovascular disease and concomitant renal dysfunction, 
because they are preferentially eliminated via the liver without 
much interference with other drugs. Like ACE inhibitors, renin 
inhibitors behave as vasodilators with the potential to improve 
the elasticity of the large arteries. Conversely, they are likely to 
be subject to the same contraindications as ACE inhibitors and 
angiotensin-receptor blockers, such as pregnancy and bilateral 
renal-artery stenoses. (Lancet 2006; 368: 1449–1456)
Marc De Broe
Renal cortical cyclooxygenase 
2 is differentially regulated 
by angiotensin II AT1 and AT2 
receptors
In the kidney, there is a complex and multilayered interaction 
between the renin–angiotensin and prostaglandin systems. 
For example, although, under steady-state normal conditions, 
inhibition of the enzymes that initiate prostaglandin synthesis, 
cyclooxygenases (COXs), does not profoundly aff ect renal 
function, COX inhibition in conditions with increased 
angiotensin II production causes signifi cant changes in renal 
hemodynamics and function.
Of the two COX enzymes, COX-1 in the kidney is localized 
to mesangial cells, arteriolar endothelial cells, parietal epithelial 
cells of Bowman’s capsule, and cortical and medullary collecting 
ducts. In contrast, COX-2 expression is localized to the macula 
densa and associated cortical thick ascending limb of Henle in 
the cortex and to a subset of medullary interstitial cells near the 
papillary tip. Aft er chronic salt depletion, COX-2 expression in 
the macula densa increases signifi cantly, and macula densa-
derived COX-2 metabolites have been implicated as modulators 
of the renin–angiotensin action by increasing renin expression 
and secretion from juxtaglomerular cells of the aff erent arteriole 
as well as serving as vasodilatory agents for aff erent arterioles to 
maintain glomerular perfusion.
In vivo administration of either an ACE inhibitor or an 
angiotensin type 1 (AT1) receptor blocker (ARB) increases 
cortical COX-2 expression, and mice with genetic deletion 
of both AT1 subtype genes expressed increased COX-2 in 
the macula densa, suggesting that angiotensin II inhibits 
COX-2 expression in macula densa cells. However, these 
studies could not distinguish whether the observed changes 
in COX-2 expression were a receptor-mediated direct eff ect 
of angiotensin on COX-2 regulation or were secondary to 
systemic hemodynamic eff ects. To address this question, 
Zhang et al. infused either hypertensive or nonhypertensive 
concentrations of angiotensin II and found that cortical COX-2 
expression decreased (see Figure). In addition, angiotensin 
II infusion reversed the cortical COX-2 elevation induced 
by ACE inhibitors; importantly, the authors also found that 
angiotensin II infusion further stimulated cortical COX-2 
elevation induced by ARBs, suggesting a potential role for an 
AT2 receptor-mediated pathway when the AT1 receptor was 
inhibited. To test this, they treated wild-type and AT2 receptor 
knockout mice with either ACE inhibitors or ARBs. Cortical 
COX-2 increased to similar levels in response to ACE inhibition 
in both knockout and wild-type mice. In contrast, ARBs 
increased cortical COX-2 in the wild type more than ACE 
inhibitors did, and this stimulation was attenuated by the AT2 
receptor antagonist PD123319. In the knockout mice, ARBs led 
to signifi cantly less cortical COX-2 elevation, which was not 
attenuated by PD123319. Polymerase chain reaction confi rmed 
that a cultured macula densa cell line contained AT1a and AT2 
receptors. Angiotensin II inhibited COX-2 in these cells, and 
an AT2 receptor agonist stimulated COX-2. In summary, this 
work demonstrated that macula densa COX-2 expression is 
oppositely regulated by AT1 and AT2 receptors and suggests that 
AT2 receptor-mediated cortical COX-2 elevation may mediate 
physiologic eff ects that modulate AT1-mediated responses. 
(Proc Natl Acad Sci USA 2006; 103: 16045–16050)
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COX-2 expression in kidney cortex. As compared with control rats 
(a), reduced COX-2-ir in the macula densa was observed in rats with 
angiotensin II infusion (b), and increased COX-2-ir was observed in rats 
with angiotensin receptor blocker (ARB) treatment (c).
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Calcineurin regulation 
of pancreatic β-cells and 
post-transplant diabetes
Diabetes is a frequent complication in patients with organ 
transplants, and its development is associated with a 
variety of drugs, such as glucocorticoids and calcineurin 
inhibitors. Calcineurin is a Ca++ and calmodulin-dependent 
phosphatase that dephosphorylates numerous sites within the 
regulatory region of NFAT (nuclear factor of activated T cells) 
transcription factors, originally described as regulators of the 
activity of the interleukin-2 in T lymphocytes. Calcineurin 
action activates four NFATc proteins (NFATc1, -c2, -c3 
and -c4), stimulating their cytosolic–nuclear translocation 
and subsequent DNA binding. Conversely, without active 
calcineurin, the activity of NFAT factors is suppressed, T-cell 
activation is blocked, and rejection of transplanted organs is 
prevented. To study the role of the calcineurin–NFAT pathway 
in the genesis of diabetes, Heit et al. generated mice with a β-
cell-specifi c deletion of the calcineurin phosphatase regulatory 
subunit, calcineurin b1 (Cnb1). Th ese mice developed 
age-dependent diabetes characterized by decreased β-cell 
proliferation and mass, reduced pancreatic insulin content, and 
hypoinsulinemia. Moreover, β-cells lacking Cnb1 had reduced 
expression of established regulators of β-cell proliferation. 
Conditional expression of active NFATc1 in Cnb1-defi cient β-
cells rescued these defects and prevented diabetes. Conversely, 
in normal adult β-cells, conditional NFAT activation promoted 
the expression of cell-cycle regulators and increased β-cell 
proliferation and mass, resulting in hyperinsulinemia. 
Conditional NFAT activation also induced the expression 
of genes critical for β-cell endocrine function, including all 
six genes mutated in hereditary forms of monogenic type 2 
diabetes. Th us, calcineurin–NFAT signaling regulates multiple 
factors that control growth and hallmark β-cell functions, 
revealing unique models for the pathogenesis and therapy of 
diabetes and illuminating the pathogenesis of post-transplant 
diabetes. (Nature 2006; 443: 345–349)
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Branching morphogenesis in vitro
Th e treelike structures present in many organs containing 
tubules are generated by branching morphogenesis, a 
reiterative process of branch initiation and invasion from a 
preexisting epithelium. Th e overall process is regulated by 
a number of cues, including growth factors, extracellular 
matrix molecules, proteases, and morphogens. Th ese cues 
must be integrated locally within the context of the tissue to 
determine where branches are initiated; thus, a subgroup of 
epithelial cells is instructed to form a branch or to bifurcate, 
whereas neighboring cells are not. Current techniques to study 
this process, which is common to many organs, including 
the kidney, lung, and mammary and salivary glands, do not 
allow for a precise quantitative understanding of how spatial 
positioning is determined. Nelson et al. have developed a 
three-dimensional assay for mammary epithelial branching 
morphogenesis that mimics branching in the mammary gland 
and that allows control of the initial geometry of tubules as well 
as quantifi cation of the positions at which they branch. Th ey 
embedded normal mouse mammary epithelial cells in cavities 
of collagen gels. Th e cells developed epithelial tubules of 
defi ned geometry, and the position of branching depended on 
the initial geometry of the tubule. Branching required cellular 
proliferation, but the pattern of branching was not due to 
localized proliferation or locally enhanced signaling by growth 
factor receptors. Because there were no mesenchymal cells in 
this system, the authors postulated that branching position 
was determined by autocrine inhibitory morphogens secreted 
by the epithelial cells themselves and that their concentration 
would be lowest at the branching sites (see Figure). Indeed, 
they found that the cells secreted transforming growth factor-
β1 and that its concentration in the gel was lowest at the 
branching sites.
Th is elegant study demonstrated that tissue form and 
context — including the geometry of multicellular tubules, 
as well as their proximity to neighbors — can control the 
position of branching during morphogenesis of mammary 
epithelial cells and primary organoids. Th at this simple ex vivo 
system exhibits complex bifurcating and lateral branching 
behaviors suggests that the geometry of the duct may act as an 
instructive cue during its morphogenesis in vivo. Th e model of 
Nelson et al. allows direct quantitative testing of the positional 
integration of stimulatory and inhibitory cues that control 
morphogenesis of any branched organ system, including the 
kidney. (Science 2006; 314: 298–300)
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Branching position is determined by tubule geometry and is consistent 
with the concentration profile of secreted diffusible inhibitors.
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